| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
169,860,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
16,666,666 |
16,666,666 |
16,666,666 |
33,511,676 |
| Total Buy Value |
$349,999,986 |
$349,999,986 |
$349,999,986 |
$686,900,186 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
2 |
| Total Shares Sold |
63,868 |
71,840 |
173,935 |
501,793 |
| Total Sell Value |
$1,538,409 |
$1,682,318 |
$3,288,562 |
$12,835,902 |
| Total People Sold |
5 |
6 |
9 |
12 |
| Total Sell Transactions |
6 |
10 |
26 |
85 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stout Jay S |
Chief Technology Officer |
• – – |
2026-01-21 |
4 |
S |
$26.03 |
$51,461 |
D/D |
(1,977) |
197,634 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2026-01-07 |
4 |
S |
$26.51 |
$31,914 |
D/D |
(1,203) |
199,611 |
|
- |
|
| Van Tuyl Christopher |
Chief Legal Officer |
• – – |
2025-12-18 |
4 |
S |
$26.78 |
$290,943 |
D/D |
(10,813) |
149,930 |
|
- |
|
| Roivant Sciences Ltd. |
|
• • • |
2025-12-12 |
4 |
B |
$21.00 |
$349,999,986 |
D/D |
16,666,666 |
113,317,007 |
0.01 |
- |
|
| Hughes Douglas J. |
Director |
– • – |
2025-12-01 |
4 |
AS |
$23.14 |
$348,665 |
D/D |
(15,000) |
120,773 |
|
- |
|
| Fromkin Drew J |
Director |
– • – |
2025-12-01 |
4 |
AS |
$23.14 |
$517,189 |
D/D |
(22,249) |
85,852 |
|
- |
|
| Gloria Melanie |
Chief Operating Officer |
• – – |
2025-11-20 |
4 |
S |
$23.54 |
$298,237 |
D/D |
(12,626) |
173,511 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2025-10-22 |
4 |
S |
$19.03 |
$49,383 |
D/D |
(2,595) |
217,958 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-10-22 |
4 |
S |
$19.03 |
$47,956 |
D/D |
(2,520) |
200,814 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2025-10-08 |
4 |
S |
$16.30 |
$20,734 |
D/D |
(1,272) |
220,553 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-10-08 |
4 |
S |
$16.30 |
$25,836 |
D/D |
(1,585) |
203,334 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2025-07-23 |
4 |
S |
$18.15 |
$43,288 |
D/D |
(2,385) |
221,825 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-07-23 |
4 |
S |
$18.15 |
$50,911 |
D/D |
(2,805) |
204,919 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2025-07-09 |
4 |
S |
$17.24 |
$19,998 |
D/D |
(1,160) |
224,210 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-07-09 |
4 |
S |
$17.24 |
$26,188 |
D/D |
(1,519) |
207,724 |
|
- |
|
| Susman Robert Graham |
|
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,016 |
25,016 |
|
- |
|
| Bauer Jake |
|
– • – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,016 |
25,016 |
|
- |
|
| Girao Tiago |
Chief Financial Officer |
• – – |
2025-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
208,388 |
208,388 |
|
- |
|
| Geffner Michael |
Chief Medical Officer |
• – – |
2025-04-23 |
4 |
S |
$14.79 |
$34,742 |
D/D |
(2,349) |
225,370 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-04-23 |
4 |
S |
$14.79 |
$28,471 |
D/D |
(1,925) |
209,243 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2025-04-16 |
4 |
S |
$14.89 |
$123,900 |
D/D |
(8,321) |
1,178,191 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2025-04-16 |
4 |
S |
$14.89 |
$44,566 |
D/D |
(2,993) |
396,774 |
|
- |
|
| Barnett Eva Renee |
Chief Financial Officer |
• – – |
2025-04-09 |
4 |
S |
$12.99 |
$143,708 |
D/D |
(11,063) |
399,767 |
|
- |
|
| Salzmann Peter |
Chief Executive Officer |
• • – |
2025-04-09 |
4 |
S |
$12.99 |
$364,941 |
D/D |
(28,094) |
1,186,512 |
|
- |
|
| Stout Jay S |
Chief Technology Officer |
• – – |
2025-04-09 |
4 |
S |
$12.99 |
$65,002 |
D/D |
(5,004) |
211,168 |
|
- |
|
272 Records found
|
|
Page 1 of 11 |
|
|
